NASDAQ:TTNP - Nasdaq - US8883147055 - Common Stock - Currency: USD
3.7
-0.09 (-2.37%)
The current stock price of TTNP is 3.7 USD. In the past month the price decreased by -4.39%. In the past year, price decreased by -47.81%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 68.04 | 838.54B | ||
JNJ | JOHNSON & JOHNSON | 15.38 | 372.51B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 17.99 | 275.58B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.12 | 221.49B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.69B | ||
MRK | MERCK & CO. INC. | 10.62 | 208.21B | ||
PFE | PFIZER INC | 7.37 | 129.99B | ||
SNY | SANOFI-ADR | 13.59 | 128.08B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.53 | 97.47B | ||
GSK | GSK PLC-SPON ADR | 8.6 | 75.84B | ||
ZTS | ZOETIS INC | 25.92 | 68.46B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.67 | 47.30B |
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
TITAN PHARMACEUTICALS INC
Suite 505, 400 Oyster Point Blvd
San Francisco CALIFORNIA 94080 US
CEO: Marc Rubin
Employees: 4
Company Website: https://www.titanpharm.com/
Investor Relations: http://ir.titanpharm.com/
Phone: 14152444990
The current stock price of TTNP is 3.7 USD. The price decreased by -2.37% in the last trading session.
The exchange symbol of TITAN PHARMACEUTICALS INC is TTNP and it is listed on the Nasdaq exchange.
TTNP stock is listed on the Nasdaq exchange.
TITAN PHARMACEUTICALS INC (TTNP) has a market capitalization of 3.37M USD. This makes TTNP a Nano Cap stock.
TITAN PHARMACEUTICALS INC (TTNP) currently has 4 employees.
TITAN PHARMACEUTICALS INC (TTNP) has a support level at 3.59 and a resistance level at 3.7. Check the full technical report for a detailed analysis of TTNP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TTNP does not pay a dividend.
TITAN PHARMACEUTICALS INC (TTNP) will report earnings on 2025-05-13.
TITAN PHARMACEUTICALS INC (TTNP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.23).
The outstanding short interest for TITAN PHARMACEUTICALS INC (TTNP) is 1.46% of its float. Check the ownership tab for more information on the TTNP short interest.
ChartMill assigns a technical rating of 1 / 10 to TTNP. When comparing the yearly performance of all stocks, TTNP is a bad performer in the overall market: 78.94% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to TTNP. While TTNP seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months TTNP reported a non-GAAP Earnings per Share(EPS) of -5.23. The EPS increased by 29.34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -161% | ||
ROE | -192.87% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to TTNP. The Buy consensus is the average rating of analysts ratings from 6 analysts.